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POINT OF VIEW
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ABSTRACT
The analysis of DNA methylation has become routine in the pipeline for diagnosis of imprinting disorders,
with many publications reporting aberrant methylation associated with imprinted differentially
methylated regions (DMRs). However, comparisons between these studies are routinely hampered by the
lack of consistency in reporting sites of methylation evaluated. To avoid confusion surrounding
nomenclature, special care is needed to communicate results accurately, especially between scientists and
other health care professionals. Within the European Network for Human Congenital Imprinting Disorders
we have discussed these issues and designed a nomenclature for naming imprinted DMRs as well as for
reporting methylation values. We apply these recommendations for imprinted DMRs that are commonly
assayed in clinical laboratories and show how they support standardized database submission. The
recommendations are in line with existing recommendations, most importantly the Human Genome
Variation Society nomenclature, and should facilitate accurate reporting and data exchange among
laboratories and thereby help to avoid future confusion.
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Mammalian genomic imprinting is an epigenetic regulatory
mechanism that results in parent-of-origin speciﬁc gene expres-
sion in diploid somatic cells (for a review, see ref1). Several fea-
tures of the imprinting mechanism have been identiﬁed
including allelic DNA methylation, histone modiﬁcations, and
noncoding RNAs.2 Clustering and coordinate regulation is a
key feature of imprinted domains with much effort invested in
understanding how multiple genes are regulated by long-range
cis-acting differentially methylated regions (DMRs).
In 1993, two publications reported parent-of-origin speciﬁc
methylation associated with imprinted domains. Both of these
studies were in mouse, the ﬁrst described the paternally methyl-
ated regions associated with the H19-Igf2 gene cluster,3 the sec-
ond identiﬁed a region of methylation on the maternal allele
within the Igf2r gene associated with the T-associated maternal
effect (Tme) deletion.4 Since these ﬁrst pivotal reports, with the
advent of genome-wide methylation screening technologies,
the number of imprinted DMRs in mammalian species has
steadily increased, including those originating from the respec-
tive germlines and those that are somatically acquired.
Primary methylation defects of some well characterized
imprinted DMRs are directly responsible for developmental
disorders, including Beckwith-Wiedemann syndrome
(OMIM 130,650) (BWS), Silver-Russell syndrome (OMIM
180,860) (SRS), Transient Neonatal Diabetes Mellitus (OMIM
601,410) (TNDM), Kagami-Ogata syndrome (OMIM
608,149) (KOS14), Temple syndrome (OMIM 616,222)
(TS14), Prader-Willi syndrome (OMIM 176,270) (PWS),
Angelman syndrome (OMIM 105,830) (AS), and Pseudohypo-
parathyroidism Ib (OMIM 103,580) (PHP1b) (a detailed
description of human imprinting disorders is available at the
webpage of the European Network for Human Congenital
Imprinting Disorders, EUCID.net). The aberrant methylation
often affects solely the disease-associated locus but, recently,
some individuals have been reported to have additional
imprinted DMRs affected, leading to a scenario termed multi-
locus imprinting disturbance (MLID) (for a review, see ref5).
Reporting these epigenomic data from molecular tests in
laboratory reports or for publication is troubled by the lack
of a uniform nomenclature. In this article we recommend uni-
ﬁed names for imprinted DMRs and give details of their pre-
cise locations and suggest nomenclature for describing the
results similar to those routinely used for DNA sequence
variants.
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Consensus for names of imprinted DMR
From the earliest days of the molecular descriptions of imprint-
ing aberrations it became obvious that recording methylation
defects would be challenging. This was evident simply because
some imprinted genes have historically had multiple names,
since many were identiﬁed simultaneously by independent
groups who have termed the transcripts and DMRs differently.
This is exempliﬁed by the maternally methylated region over-
lapping the promoter of KCNQ1OT1 within intron 10 of
KCNQ1 on chromosome 11, which has more than ﬁve aliases
(Table 1). Ultimately, this causes confusion when cross-
referencing original literature and modern databases. To
improve this situation, the 41 EUCID members from 22 coun-
tries, have developed a uniform nomenclature system for
reporting methylation aberrations. The ﬁnal consensus after
careful consideration was that the name of an imprinted DMR
should be attributed to the nearest transcript with an approved
symbol from the Human Genome Organization (HUGO) Gene
Nomenclature Committee (HGNC).
Furthermore, we named a DMR in such a way that it gives basic
information regarding its localization in relation to the nearest
RefSeq transcript with the use of several preﬁxes outlined in Fig. 1
(e.g., TSS for transcription start site, IG for intergenic, Int for
intronic and alt-TSS for alternative transcription start site). The
precise location of each imprinted DMR is derived from methyl-
seq data from whole blood samples as described by Court et al.,6
which has base-pair resolution. To ensure that the same genomic
regions are identiﬁable in subsequent genome builds, all imprinted
domains, including their corresponding DMRs, have been submit-
ted to obtain Locus Reference Genomic (LRG) identiﬁers.7 LRGs
are manually curated reference sequence records speciﬁcally
designed for the reporting of variants with clinical implications.
The inclusion of stable and unique genomic, transcript, and protein
reference sequences ensures that variants are unambiguously and
consistently reported over time (www.lrg-sequence.org). The
records will contain all relevant DMR annotations. Information
regarding the recommended naming, localization, and sizes of
each DMR are given in Table 1.
Standardization of reporting exact sites of imprinted
methylation
It has previously been discussed that in order to allow correct
identiﬁcation and eventual reproduction of published observa-
tions, a universal system for the description of speciﬁc sites of
DNA methylation tested needs to be employed.8 In the case of
imprinted DMRs, this is reasonably straightforward if laborato-
ries use commercially available methods to analyze methylation,
such as methylation-sensitive multiplex ligation-dependent probe
ampliﬁcations (MLPA) or high-density methylation arrays. In
such cases, the precise location of the probe identiﬁer, restriction
site, or the interrogated CpG probes found on commonly used
methylation proﬁling platforms can easily be identiﬁed, the geno-
mic nucleotide tested accurately described, and methylation val-
ues reported. As an initial step to assist in this standardization,
we have provided a resource listing all probes mapping to
imprinted DMRs on the popular Inﬁnium HumanMethyla-
tion450 BeadChips (Illumina, USA)(Suppl. Table 1), as well as
the CpG dinucleotides interrogated by commonly used methyla-
tion-sensitive MLPA kits (MRC Holland, Netherlands)(Suppl.
Table 2). For custom technologies, such as in-house pyrose-
quencing, for example, different CpG positions within the
imprinted DMRs may be examined. In such cases, we recom-
mend that the genomic coordinates targeted by the assays be
listed and the methylation status described as an average per-
centage of all CpGs analyzed. However, such a description lacks
resolution at the individual CpG level and, for future standard-
ized reporting, it would be advantageous to have this informa-
tion, not only for methylation at imprinted DMRs but also for
all CpG positions in the genome. Such an approach could be
based upon the current annotation of genomic locations as rec-
ommended by the Human Genome Variation Society (HGVS),
allowing methylation values to be paired to each CpG
position.9,10
Use of the suggested nomenclature
Following HGVS recommendations, methylation values at a
speciﬁc region are described with (A) the chromosome
number or LRG followed by (B) a colon :“;” (C) preﬁx “g.”
for genomic DNA; (D) the position of the cytosine nucleo-
tide or the range of nucleotides tested for the CpG contain-
ing interval; (E) the “j” character to indicate that it is a
modiﬁcation of the sequence not a sequence variant; (F)
preﬁx describing the speciﬁc modiﬁcation.
In collaboration with the HGVS’ Sequence Variant Descrip-
tion Working Group (SVD-WG), it was decided to use the
abbreviation “gom” to report a gain of methylation and “lom”
for a loss. For non-speciﬁc methylation resistant to bisulphite
conversion we suggest “bis” followed by a methylation value in
brackets. If the molecular assay differentiates between 5-meth-
ylcytosine and its oxidative derivative 5-hydroxymethylcyto-
sine, we propose the use of the “met” and “hmt,” respectively.
This is consistent with HGVS standards to use three-letter
abbreviations that do not include the nucleotide so that the
modiﬁcation can be added to any DNA base. When utilizing
this format, it is important to mention the correct imprinted
DMR name, the genome build used, and the technique used to
measure the methylation status. This is because the EUCID
COST action has previously reported that different methods
targeting subtly different locations within the same imprinted
DMR having different sensitivities.11,12 Furthermore, to help
characterize variation due to tissue mosaicism, the tissue source
from which the DNA is derived should be stated in any report
because the methylation levels can be different in different
tissues.13
For example, the nomenclature for a bisulphite PCR target-
ing the KCNQ1OT1:TSS-DMR negative DNA strand:
GRCh37/hg19 chr11:g. 2,722,063_ 2,722,087, in detail chr11:g.
2,722,063_ 2,722,087jmet {0.52} indicates that the CpGs within
this 24 bp interval have an average methylation of 52%. Using the
LRGs, the nomenclature would be LRG_1,052:g.94506_94,530;
LRG_1,052:g.94506_94,530jmet {0.52}. For an example with loss
of methylation of the same interval, the nomenclature would be
GRCh37/hg19 chr11:g.2722063_ 2,722,087jlom, in detail chr11:g.
2,722,063_ 2,722,087jmet {0.22} or LRG_1,052:g.94506_94,530;
LRG_1,052:g.94506_94,530jmet {0.22}.
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An example of the same region reporting methylation at
individual cytosines of CpG dinucleotides would be:
GRCh37/hg19 chr11:g. 2722063Cjmet {0.50}; 2722072Cjmet
{0.54}; 2722074Cjmet {0.52}; 2722077Cjmet {0.53};
2722083Cjmet {0.50}; 2722085Cjmet {0.51}; 2722087Cjmet
{0.55} or LRG_1,052:g.94506Cjmet {0.50}; 94515Cjmet {0.54};
94517Cjmet {0.52}; 94520Cjmet {0.53}; 94526Cjmet {0.50};
94528Cjmet {0.51}; 94530Cjmet {0.55} in the sample with
normal methylation. For the sample with loss of methylation,
the nomenclature would be GRCh37/hg19 chr11:g.
Table 1. The extent of imprinted methylation deﬁned by methyl-seq data sets with the commonly used name for each imprinted DMR, those proposed by of EUCID using
HGNC approved gene names, previous aliases and LRG identiﬁers. For completeness, origin of the allelic methylation is given, as are any associated disorders and informa-
tion whether the methylation is germline or somatically derived. Secondary DMRs are regions of differential methylation, the establishment of which is often somatically
acquired and dependent on hierarchical interactions with a neighboring germline DMR. All coordinates are given as GRCh37/hg19. M, maternally derived methylation; P,
paternally derived methylation; gDMR, germline DMR; PHP1b, Pseudohypoparathyroidism; SRS, Silver Russell syndrome; BWS, Beckwith Wiedemann syndrome; AS, Angel-
man syndrome; PWS, Prader Willi syndrome; MLID, Mutlilocus imprinting disturbance; TS14, Temple syndrome; KOS14, Kagami-Ogata syndrome; TNDM, Transient Neona-
tal Diabetes Mellitus. All relevant DMR information and aliases can also be found in the “community” section of each LRG record.
Extent of DMR
(methyl-seq)
Imprinted DMR
name Chr Start Finish
Number
CpGs
Methylation
origin Germline derived
LRG
identiﬁer Aliases
PPIEL:Ex1-DMR 1 40,024,626 40,025,540 39 M Oocyte gDMR
DIRAS3:TSS-DMR 1 68,515,433 68,517,545 88 M Oocyte gDMR LRG_1,034 NOEY2, ARH1
DIRAS3:Ex2-DMR 1 68,512,505 68,513,486 39 M Oocyte gDMR LRG_1,034
GPR1-AS:TSS-DMR 2 207,066,967 207,069,445 86 M Oocyte gDMR
ZDBF2/GPR1:IG-DMR 2 207,114,583 207,136,544 439 P Sperm gDMR-secondary DMR LRG_1,065
NAP1L5:TSS-DMR 4 89,618,184 89,619,237 57 M Oocyte gDMR LRG_1,072
VTRNA2–1:DMR 5 135,414,802 135,416,645 76 M Oocyte gDMR nc886
FAM50B:TSS-DMR 6 3,849,082 3,850,359 90 M Oocyte gDMR LRG_1,062
PLAGL1:alt-TSS-DMR 6 144,328,078 144,329,888 143 M Oocyte gDMR LRG_1,101 LOT1, ZAC1
IGF2R:Int2-DMR 6 160,426,558 160,427,561 74 M Oocyte gDMR LRG_1,036
WDR27:Int13-DMR 6 170,054,504 170,055,618 58 M Oocyte gDMR LRG_1,071
GRB10:alt-TSS-DMR 7 50,848,726 50,851,312 171 M Oocyte gDMR LRG_1,032
PEG10:TSS-DMR 7 94,285,537 94,287,960 119 M Oocyte gDMR LRG_1,097
MEST:alt-TSS-DMR 7 130,130,122 130,134,388 226 M Oocyte gDMR LRG_1,033 PEG1
SVOPL:alt-TSS-DMR 7 138,348,118 138,349,069 31 M Oocyte gDMR LRG_1,103
HTR5A:TSS-DMR 7 154,862,719 154,863,382 55 M Oocyte gDMR LRG_1,057
ERLIN2:Int6-DMR 8 37,604,992 37,606,088 37 M Oocyte gDMR LRG_1,040
PEG13:TSS-DMR 8 141,108,147 141,111,081 193 M Oocyte gDMR LRG_1,041 TRAPPC9 intronic DMR
FANCC:Int1-DMR 9 98,075,400 98,075,744 26 M Oocyte gDMR LRG_497
INPP5F:Int2-DMR 10 121,578,046 121,578,727 52 M Oocyte gDMR LRG_1,061
H19/IGF2:IG-DMR 11 2,018,812 2,024,740 250 P Sperm gDMR LRG_1,030 ICR1, IC1, H19 DMR, H19
DMD,IGF2-H19 DMR
IGF2:Ex9-DMR 11 2,153,991 2,155,112 63 P No-secondary DMR LRG_1,031
IGF2:alt-TSS-DMR 11 2,168,333 2,169,768 33 P Sperm gDMR LRG_1,031
KCNQ1OT1:TSS-DMR 11 2,719,948 2,722,259 192 M Oocyte gDMR LRG_1,052 ICR2, IC2, KvDMR1,
KvLQT1-A, LIT1
RB1:Int2-DMR 13 48,892,341 48,895,763 195 M Oocyte gDMR LRG_517
MEG3/DLK1:IG-DMR 14 101,275,427 101,278,058 64 P Sperm gDMR LRG_1,044 GLT2-DLK1
MEG3:TSS-DMR 14 101,290,524 101,293,978 188 P No-secondary DMR LRG_1,098 GTL2
MEG8:Int2-DMR 14 101,370,741 101,371,419 43 M No-secondary DMR LRG_1,058
MKRN3:TSS-DMR 15 23,807,086 23,812,495 109 M Oocyte gDMR-secondary
DMR
LRG_1,045
MAGEL2:TSS-DMR 15 23,892,425 23,894,029 51 M No-secondary DMR LRG_1,046
NDN:TSS-DMR 15 23,931,451 23,932,759 108 M No-secondary DMR LRG_1,047
SNRPN:alt-TSS-DMR 15 25,068,564 25,069,481 19 M No-secondary DMR
SNRPN:Int1-DMR1 15 25,093,008 25,193,829 44 M No-secondary DMR
SNRPN:Int1-DMR2 15 25,123,027 25,123,905 45 M No-secondary DMR
SNURF:TSS-DMR 15 25,200,004 25,201,976 113 M Oocyte gDMR
IGF1R:Int2-DMR 15 99,408,496 99,409,650 55 M Oocyte gDMR LRG_1,055 IRAIN
ZNF597:30 DMR 16 3,481,801 3,482,388 29 M Oocyte gDMR LRG_1,066
ZNF597:TSS-DMR 16 3,492,828 3,494,463 76 P No-secondary DMR LRG_1,066 NAT15
ZNF331:alt-TSS-
DMR1
19 54,040,510 54,042,212 125 M Oocyte gDMR LRG_1,068
ZNF331:alt-TSS-
DMR2
19 54,057,086 54,058,425 102 M Oocyte gDMR LRG_1,068
PEG3:TSS-DMR 19 57,348,493 57,353,271 221 M Oocyte gDMR ZIM2, ZNF904
MCTS2P:TSS-DMR 20 30,134,663 30,135,933 47 M Oocyte gDMR psiMCT-1, MCTS2
NNAT:TSS-DMR 20 36,148,604 36,150,528 135 M Oocyte gDMR LRG_1,048 PEG5
L3MBTL1:alt-TSS-
DMR
20 42,142,365 42,144,040 84 M Oocyte gDMR LRG_1,049 ZC2HC3,KIAA0681
GNAS-NESP:TSS-DMR 20 57,414,039 57,418,612 257 P No-secondary DMR LRG_1,051 NESP55
GNAS-AS1:TSS-DMR 20 57,425,649 57,428,033 128 M Oocyte gDMR LRG_1,051 NESP-AS
GNAS-XL:Ex1-DMR 20 57,428,905 57,431,463 200 M Oocyte gDMR LRG_1,051 secretogranin VI
GNAS A/B:TSS-DMR 20 57,463,265 57,465,201 198 M No-secondary DMR LRG_1,051 secretogranin VI
WRB:alt-TSS-DMR 21 40,757,510 40,758,276 43 M Oocyte gDMR LRG_1,060
SNU13:alt-TSS-DMR 22 42,077,774 42,078,873 63 M Oocyte gDMR LRG_1,102 NHP2L1
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2722063Cjmet {0.22}; 2722072Cjmet {0.26}; 2722074Cjmet
{0.23}; 2722077Cjmet {0.17}; 27220783Cjmet{0.16}; 2722085Cjmet
{0.26}; 2722087Cjmet {0.26} or LRG_1,052: g.94506Cjmet {0.22};
94515Cjmet {0.26}; 94517Cjmet {0.23}; 94520Cjmet {0.17};
94526Cjmet{0.16};94528Cjmet{0.26};94530Cjmet{0.26}.
In light of our suggestions, we encourage comments and dis-
cussion from clinical geneticists, molecular geneticists, and
researchers from the epigenomics community and trust that
the recommendations we have made for standardized reporting
format will be useful for accurately communicating results. To
give the wider epigenetics community the opportunity to be
involved in the ﬁnal discussions the proposed gom/lom
nomenclature is open for community consultation on the
HGVS webpage (see http://varnomen.hgvs.org/bg-material/con
sultation/svd-wg005/). We hope that by giving precise methyla-
tion values as percentages, it will overcome issues of comparing
results between laboratories who often describe abnormalities
using different methylation indexes.
The next issue that needs a consensus is deﬁning the criteria
to allow the description ‘lom’ or ‘gom’. This is complicated as
not only statistical cut-offs need to be discussed (i.e., using
mean § standard deviation), but also the number of controls
analyzed to deﬁne the normal range. Furthermore, utilizing
ﬁxed statistical criteria will be complicated in cases with mosaic
epimutations, as methylation variance at different CpGs within
a DMR need to be taken into account, as does the reproducibil-
ity of the molecular techniques used. 11
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Figure 1. Schematic overview of the naming system for imprinted DMRs. The upper panel shows the three imprinted DMRs located within the chromosome 14q32.2
domain depicting (A) an intergenic DMR, (B) a DMR overlapping a transcription start site, and (C) an intronic DMR. The lower panel illustrates a DMR associated with (D)
an alternative ﬁrst exon as found within the PLAGL1 locus on chromosome 6q24. Black boxes represent methylated regions while open boxes are unmethylated. Blue
arrows signify paternally expressed genes, red arrows denote maternally expressed genes, and gray arrows are biallelically expressed transcripts.
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